Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Event Details


Companion Diagnostics Forum (CDx) 2017

Add this event to your calendar: iCal   Google Calendar

Who should attend?

Talk Topics this year cover: Importance of CDx for Biologics and Small Molecule Drugs – creating therapeutic and market value for patient-centric treatments Evolving CDx from animal models: From proof of concept (POC) to generating biomarker candidates; drug dosing; and response tracking Informatics for analyzing Big Data sets to develop CDx candidates Regulatory issues to be addressed during development Technologies to identify markers We welcome researchers in biotechnology organizations ranging from start-up companies to leading-edge suppliers to non-profit institutions and encourage participation on the Program Committee as well as talk submissions. Attendees at this event typically range from Development to Post-Marketing Surveillance in biomarkers (development) and diagnostics (market offerings). Expected Attendees include (see 2016 Attendee List for last year’s Attendees): VPs in Translational Medicine and related functions Executive/Senior Directors Laboratory and Technology Directors Project Managers (technical, logistical, and transitioning projects to partners) Technology leaders and researchers (assays, platforms, informatics) Researchers in assays, diagnostics (basic, development, validation, execution) Allied VP, Executive/Senior Directors, Directors, and Associates in licensing and regulatory


Companion diagnostics (CDx) and Complementary Diagnostics have been on the market and used to treat diseases for several years. Notable examples of Companion Diagnostics include Xalkori and Ventana ALK (D5F3) CDx Assay; Gleevec and Dako C-KIT PharmDx; Keytruda and Dako PD-L1 IHC 22C3 pharmDx; Tarceva and cobas® EGFR Mutation Test v2; and Herceptin and Pathvysion HER-2 DNA Probe Kit. Not only must CDx-drug pairs demonstrate therapeutic utility, drug companies and their business partners must realize net financial benefits.   In this symposium, examples and strategies to pair drugs and assays to improve safety, efficacy, outcomes, and economic value will be presented and discussed.


$1095 Early Bird Discount $200 until 11/1/17


Tom Fare

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.